Terms: = Breast cancer AND PR, PGR, progesterone receptor AND Clinical Outcome
358 results:
1. Conditional generative adversarial network driven radiomic prediction of mutation status based on magnetic resonance imaging of breast cancer.
Huang ZH; Chen L; Sun Y; Liu Q; Hu P
J Transl Med; 2024 Mar; 22(1):226. PubMed ID: 38429796
[TBL] [Abstract] [Full Text] [Related]
2. Tumor budding in breast carcinoma: A systematic review and meta-analysis.
Buch A; Khan U; Rathod H; Jain K; Dwivedi A; Rajesh A
J Cancer Res Ther; 2023 Oct; 19(7):1697-1713. PubMed ID: 38376268
[TBL] [Abstract] [Full Text] [Related]
3. Molecular features of luminal breast cancer defined through spatial and single-cell transcriptomics.
Yoshitake R; Mori H; Ha D; Wu X; Wang J; Wang X; Saeki K; Chang G; Shim HJ; Chan Y; Chen S
Clin Transl Med; 2024 Jan; 14(1):e1548. PubMed ID: 38282415
[TBL] [Abstract] [Full Text] [Related]
4. clinical characteristics and prognosis of primary small cell carcinoma of the breast: a propensity score-matched, population-based study.
Yin L; Yin AH; Pu CC
BMJ Open; 2023 Dec; 13(12):e073841. PubMed ID: 38097248
[TBL] [Abstract] [Full Text] [Related]
5. A controversial ER negative PR positive molecular subtype of breast carcinoma-Report of two cases.
Chandra S; Bhasin S; Saini S
Breast Dis; 2023; 42(1):315-318. PubMed ID: 37807774
[TBL] [Abstract] [Full Text] [Related]
6. Estrogen receptor beta expression in triple negative breast cancers is not associated with recurrence or survival.
Takano EA; Younes MM; Meehan K; Spalding L; Yan M; Allan P; Fox SB; Redfern A; Clouston D; Giles GG; Christie EL; Anderson RL; Zethoven M; Phillips KA; Gorringe K; Britt KL
BMC Cancer; 2023 May; 23(1):459. PubMed ID: 37208678
[TBL] [Abstract] [Full Text] [Related]
7. A non-inferiority randomized phase III trial of standard immunotherapy by checkpoint inhibitors vs. reduced dose intensity in responding patients with metastatic cancer: the MOIO protocol study.
Gravis G; Marino P; Olive D; Penault-LLorca F; Delord JP; Simon C; Lamrani-Ghaouti A; Sabatier R; Ciccolini J; Boher JM
BMC Cancer; 2023 May; 23(1):393. PubMed ID: 37131154
[TBL] [Abstract] [Full Text] [Related]
8. The role of p53 and ki67 in predicting clinical outcome in breast cancer patients.
Lalkota BP; Srinivasa BJ; Swamy MV; Hazarika D; Jeet BM; Jyothi K; Ghosh M; Sayeed SM; Nasiruddin M; Naik R
J Cancer Res Ther; 2023; 19(2):208-213. PubMed ID: 37006059
[TBL] [Abstract] [Full Text] [Related]
9. ER-/PR+ breast cancer is controlled more effectively with an inflammatory inhibitor than hormonal inhibitor.
Song C; Kendi AT; Shim JY; Jung D; Kang PS; Lowe VJ; Lee S
Breast Cancer; 2023 May; 30(3):436-452. PubMed ID: 36859733
[TBL] [Abstract] [Full Text] [Related]
10. Muscle mass loss in breast cancer patients of reproductive age (≤ 45 years) undergoing neoadjuvant chemotherapy.
Rossi F; Lambertini M; Brunetti N; De Giorgis S; Razeti MG; Calabrese M; Tagliafico AS
Radiol Med; 2023 Jan; 128(1):49-57. PubMed ID: 36536266
[TBL] [Abstract] [Full Text] [Related]
11. Spatial and Quantitative Analysis of Tumor-Associated Macrophages: Intratumoral CD163-/PD-L1+ TAMs as a Marker of Favorable clinical outcomes in Triple-Negative breast cancer.
Shinohara H; Kobayashi M; Hayashi K; Nogawa D; Asakawa A; Ohata Y; Kubota K; Takahashi H; Yamada M; Tokunaga M; Kinugasa Y; Oda G; Nakagawa T; Onishi I; Kinowaki Y; Kurata M; Ohashi K; Kitagawa M; Yamamoto K
Int J Mol Sci; 2022 Oct; 23(21):. PubMed ID: 36362023
[TBL] [Abstract] [Full Text] [Related]
12. clinical outcome of embryo cryopreservation in Japanese breast cancer patients: pregnancy rates after transfer of thawed embryos.
Okutsu-Horage Y; Iwahata H; Suzuki-Takahashi Y; Sugishita Y; Takae S; Suzuki N
J Assist Reprod Genet; 2022 Aug; 39(8):1769-1777. PubMed ID: 35980490
[TBL] [Abstract] [Full Text] [Related]
13. Characterizing Clinicopathologic Features of Estrogen receptor-Positive/progesterone receptor-Negative breast cancers.
Fei F; Siegal GP; Wei S
Clin Breast Cancer; 2022 Oct; 22(7):e788-e797. PubMed ID: 35915022
[TBL] [Abstract] [Full Text] [Related]
14. Does concomitant ductal carcinoma in situ affect the clinical outcome in breast cancer patients with invasive ductal carcinoma: An Asian perspective.
Lee WP; Shetty SS; Seah CMJ; Tan PT; Tan SM
Cancer Rep (Hoboken); 2022 Sep; 5(9):e1646. PubMed ID: 35892151
[TBL] [Abstract] [Full Text] [Related]
15. Molecular crosstalk between CUEDC2 and ERα influences the clinical outcome by regulating mitosis in breast cancer.
Roy S; Saha S; Dhar D; Chakraborty P; Singha Roy K; Mukherjee C; Gupta A; Bhattacharyya S; Roy A; Sengupta S; Roychoudhury S; Nath S
Cancer Gene Ther; 2022 Nov; 29(11):1697-1706. PubMed ID: 35732909
[TBL] [Abstract] [Full Text] [Related]
16. Partial Response After Toripalimab Plus Anlotinib for Advanced Metaplastic breast Carcinoma: A Case Report.
Fu Y; Liu J; Jiang Y
Front Endocrinol (Lausanne); 2022; 13():810747. PubMed ID: 35399948
[TBL] [Abstract] [Full Text] [Related]
17. Prognostic relevance of the HER2 status of circulating tumor cells in metastatic breast cancer patients screened for participation in the DETECT study program.
Müller V; Banys-Paluchowski M; Friedl TWP; Fasching PA; Schneeweiss A; Hartkopf A; Wallwiener D; Rack B; Meier-Stiegen F; Huober J; Rübner M; Hoffmann O; Müller L; Janni W; Wimberger P; Jäger B; Pantel K; Riethdorf S; Harbeck N; Fehm T;
ESMO Open; 2021 Dec; 6(6):100299. PubMed ID: 34839105
[TBL] [Abstract] [Full Text] [Related]
18. Fulvestrant and trastuzumab in patients with luminal HER2-positive advanced breast cancer (ABC): an Italian real-world experience (HERMIONE 9).
Torrisi R; Palumbo R; De Sanctis R; Vici P; Bianchi GV; Cortesi L; Leonardi V; Gueli R; Fabi A; Valerio MR; Gambaro AR; Tagliaferri B; Pizzuti L; Cazzaniga ME; Santoro A
Breast Cancer Res Treat; 2021 Nov; 190(1):103-109. PubMed ID: 34453206
[TBL] [Abstract] [Full Text] [Related]
19. ESR1, pgr, ERBB2, and MKi67 mRNA expression in postmenopausal women with hormone receptor-positive early breast cancer: results from ABCSG Trial 6.
Filipits M; Rudas M; Singer CF; Fitzal F; Bago-Horvath Z; Greil R; Balic M; Lax SF; Halper S; Hulla W; Wu NC; Liu X; Weidler J; Bates M; Hlauschek D; Gnant M; Dubsky P
ESMO Open; 2021 Aug; 6(4):100228. PubMed ID: 34371382
[TBL] [Abstract] [Full Text] [Related]
20. Combined Estrogen receptor and progesterone receptor Level Can Predict Survival outcome in Human Epidermal Growth Factor receptor 2-positive Early breast cancer.
Chen M; Wu J; Liu D; Chen W; Lin C; Andriani L; Ding S; Huang O; He J; Chen X; Chen W; Li Y; Shen K; Zhu L
Clin Breast Cancer; 2022 Feb; 22(2):e147-e156. PubMed ID: 34244052
[TBL] [Abstract] [Full Text] [Related]
[Next]
